Natalizumab and immune cells

Archives of Neurology

Volumn 63, Issue 10, 2006, Pages 1366-1367

  McFarland, Henry F ^a   Jacobson, Steven ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG MECHANISM; EDITORIAL; HUMAN; IMMUNOCOMPETENT CELL; POLYOMA VIRUS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOSUPPRESSION; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LYMPHOCYTES; VIRAL LOAD;

EID: 33749605100     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.63.10.1366     Document Type: Editorial

References (5)

1. Scott LM, Priestley GV, Papayannopoulou T. Deletion of alpha4 integrins from adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing. Mol Cell Biol. 2003;23:9349-9360.
2. + T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol. 2006;63:1383-1387.
3. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab: unforeseen consequences. N Engl J Med. 2005;353:414-416.
4. Vago L, Cinque P, Sala E, et al. JCV-DNA and BKV-DNA in the CNS tissue and CSF of AIDS patients and normal subjects: study of 41 cases and review of the literature. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:139-146.
5. Rollison DE, Utaipat U, Ryschkewitsch C, et al. Investigation of human brain tumors for the presence of polyomavirus genome sequences by two independent laboratories. Int J Cancer. 2005;113:769-774.